Arora Puneet S. 4

What Happened
Puneet S. Arora, Chief Medical Officer of Skye Bioscience (SKYE), received a grant of 125,000 derivative shares (reported as a stock option award) on February 6, 2026. The Form 4 lists an acquisition price of $0.00 (no cash exchanged at grant on the filing), and the award is reported as an "A" (award/grant). This is an equity compensation grant rather than a market purchase or sale.

Key Details

• Transaction date: 2026-02-06; Form 4 filed: 2026-02-09 (timely — within required reporting window).
• Security: 125,000 derivative shares (stock option award) reported at $0.00 per share on the Form 4.
• Shares owned after transaction: not specified in the information provided in this summary.
• Vesting: The option vests in equal monthly installments over four years beginning January 19, 2026 (per footnote).
• No immediate sale or cashless exercise noted in the filing.

Context
This is a standard equity compensation grant to an executive and does not reflect an immediate purchase or sale of stock. For a derivative award like this, value to the insider depends on future vesting and any exercise price or market price at exercise; the filing itself does not indicate liquidation or a market view. The filing appears timely, so there’s no late-reporting concern noted.